Long-term neuropsychiatric consequences of "ecstasy" (MDMA): A review

被引:58
作者
Montoya, AG
Sorrentino, R
Lukas, SE
Price, BH
机构
[1] McLean Hosp, Dept Neurol, Belmont, MA 02478 USA
[2] McLean Hosp, Behav Psychopharmacol Res Lab, Belmont, MA 02478 USA
[3] Massachusetts Gen Hosp, Dept Neurol, Boston, MA 02114 USA
[4] Massachusetts Gen Hosp, Dept Psychiat, Boston, MA 02114 USA
[5] Harvard Univ, Sch Med, Dept Neurol, Boston, MA 02115 USA
[6] Harvard Univ, Sch Med, Dept Psychiat, Boston, MA 02115 USA
[7] Natl Inst Neurol & Neurosurg, Mexico City, DF, Mexico
关键词
D O I
10.1080/10673220216223
中图分类号
R749 [精神病学];
学科分类号
100205 ;
摘要
The recreational drug "ecstasy" (3,4-methylenedioxymethamphetamine, or MDMA) is widely used by young people throughout the world. Experimental studies indicate that MDMA damages serotonergic neurons in animals and possibly in humans. Repeated use may induce long-term neurotoxic effects, with cognitive and behavioral implications. We reviewed both the preclinical and the clinical literature to assess the evidence for persistent neuropsychiatric sequelae in humans. We focused on studies of chronic recreational use and reports of presence or absence of neurological, psychiatric, and psychological problems related to MDMA exposure. These investigations show repeated use of ecstasy to be associated with sleep, mood, and anxiety disturbances, elevated impulsiveness, memory deficits, and attention problems, which may persist for up to 2 years after cessation. In a subset of humans, particularly adolescents, depletion of serotonin by MDMA use may hasten or enhance vulnerability to a wide array of neuropsychiatric problems. Together, the studies reviewed provide substantial evidence that MDMA causes neuronal damage in animals and humans. Additional research is necessary to determine whether the MDMA-induced destruction of serotonergic neurons can have long-term and possibly permanent neuropsychiatric consequences in humans.
引用
收藏
页码:212 / 220
页数:9
相关论文
共 90 条
[1]  
Aggleton JP, 1999, BEHAV BRAIN SCI, V22, P425
[2]   PERSISTENT EFFECTS OF (+/-)3,4-METHYLENEDIOXYMETHAMPHETAMINE (MDMA, ECSTASY) ON HUMAN SLEEP [J].
ALLEN, RP ;
MCCANN, UD ;
RICAURTE, GA .
SLEEP, 1993, 16 (06) :560-564
[3]   WHAT IS THE NATURE OF THE ROLE OF THE SEROTONERGIC NERVOUS-SYSTEM IN LEARNING AND MEMORY - PROSPECTS FOR DEVELOPMENT OF AN EFFECTIVE TREATMENT STRATEGY FOR SENILE DEMENTIA [J].
ALTMAN, HJ ;
NORMILE, HJ .
NEUROBIOLOGY OF AGING, 1988, 9 (5-6) :627-638
[4]   Schizophrenia and cognitive dysmetria: A positron-emission tomography study of dysfunctional prefrontal-thalamic-cerebellar circuitry [J].
Andreasen, NC ;
OLeary, DS ;
Cizadlo, T ;
Arndt, S ;
Rezai, K ;
Ponto, LLB ;
Watkins, GL ;
Hichwa, RD .
PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA, 1996, 93 (18) :9985-9990
[5]  
Bailly D, 1999, ENCEPHALE, V25, P595
[6]   PERMANENT HUMAN PARKINSONISM DUE TO 1-METHYL-4-PHENYL-1,2,3,6-TETRAHYDROPYRIDINE (MPTP) - 7 CASES [J].
BALLARD, PA ;
TETRUD, JW ;
LANGSTON, JW .
NEUROLOGY, 1985, 35 (07) :949-956
[7]   Brain development, VII - Human brain growth spans decades [J].
Benes, FM .
AMERICAN JOURNAL OF PSYCHIATRY, 1998, 155 (11) :1489-1489
[8]   Toxic leukencephalopathy following "ecstasy" ingestion [J].
Bertram, M ;
Egelhoff, T ;
Schwarz, S ;
Schwab, S .
JOURNAL OF NEUROLOGY, 1999, 246 (07) :617-618
[9]   Relationship between the appearance of symptoms and the level of nigrostriatal degeneration in a progressive 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine-lesioned macaque model of Parkinson's disease [J].
Bezard, E ;
Dovero, S ;
Prunier, C ;
Ravenscroft, P ;
Chalon, S ;
Guilloteau, D ;
Crossman, AR ;
Bioulac, B ;
Brotchie, JM ;
Gross, CE .
JOURNAL OF NEUROSCIENCE, 2001, 21 (17) :6853-6861
[10]   Acute inflammatory CNS disease after MDMA ('ecstasy') [J].
Bitsch, A ;
Thiel, A ;
Rieckmann, P ;
Prange, H .
EUROPEAN NEUROLOGY, 1996, 36 (05) :328-329